Device Trial Radar · NCT06311773
Pivotal Trial of the Boomerang Catheter for pDVA
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 16, 2024
Primary completion
Mar 31, 2027
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- Aveera Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.
Conditions
- Chronic Limb-Threatening Ischemia
Interventions
Boomerang CatheterDevice
The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amputation Free Survival (AFS)Time frame: 6-months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Arrowhead Regional Medical Center
San Bernardino, California
24 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.